With the development of 3D-CRT, IMRT, stereotactic approaches and other advanced forms of radiation therapy, imaging has become increasingly important in the field of radiation oncology.

As molecular imaging transitions from undercard modality to mainstream tool in diagnostic imaging, the reality of personalized healthcare appears to be on the horizon. An increasing limelight placed on the modality has attracted both investors and new companies, leading to significant milestones in R&D and thus fulfilling the promise of “true” personalized medicine.